Literature DB >> 15062173

Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy.

Juanita Crook1, Michael Milosevic, Pamela Catton, Ivan Yeung, Tara Haycocks, Thao Tran, Charles Catton, Michael McLean, Tony Panzarella, Masoom A Haider.   

Abstract

PURPOSE: Permanent seed implants are accepted treatment of early stage prostate cancer. Implant quality is assessed by post implant CT-based dosimetry but prostate contours on CT images are obscured by metallic seed artefact and edema. Outcome depends on implant quality, but perceived implant quality depends on accurate prostate contouring. This study documents inter observer variation in prostate contouring on post implant CT scans. METHODS AND MATERIALS: Ten patients had implant dosimetry calculated on 4 copies of the post implant CT scan. Prostate contours from MRI-CT fusion were the gold standard for prostate edge identification. CTs were contoured by an experienced prostate brachytherapist matching CT images to the pre implant TRUS, and by 2 GU radiation oncologists experienced in conformal radiotherapy planning. Dosimetry was compared to that obtained using MRI-CT fusion in terms of D90 and V100.
RESULTS: Contours and dosimetry were not reproducible among the 3 observers. The V100's of the experienced brachytherapist differed from that of MRI-CT fusion by a mean of 2.4% compared to 9.1% and 4.4% for observers 1 and 2, and the D90 by a mean of 9.3 Gy compared to 30.3 and 14.4 Gy for observers 1 and 2.
CONCLUSIONS: Quality assessment of prostate brachytherapy based on 1 month post implant CT is difficult. This may obscure the dose-response relationship in brachytherapy as well as create problems for quality assurance in multicentre trials evaluating brachytherapy against standard modalities. Whenever possible, MRI-CT fusion should be employed to verify prostate contours post implant.

Entities:  

Mesh:

Year:  2002        PMID: 15062173     DOI: 10.1016/s1538-4721(02)00014-4

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  14 in total

1.  Preliminary study of correction of original metal artifacts due to 1-125 seeds in postimplant dosimetry for prostate permanent implant brachytherapy.

Authors:  Yutaka Takahashi; Shinichiro Mori; Takuyo Kozuka; Kotaro Gomi; Takayuki Nose; Takatoshi Tahara; Masahiko Oguchi; Takashi Yamashita
Journal:  Radiat Med       Date:  2006-02

2.  CT-based postimplant dosimetry of prostate brachytherapy: comparison of 1-mm and 5-mm section CT.

Authors:  Osamu Tanaka; Shinya Hayashi; Masayuki Kanematsu; Masayuki Matsuo; Masahiro Nakano; Sunaho Maeda; Takashi Deguchi; Hiroaki Hoshi
Journal:  Radiat Med       Date:  2007-01-25

3.  Results of a dummy run of postimplant dosimetry between multi-institutional centers in prostate brachytherapy with 125I seeds.

Authors:  Manabu Aoki; Atsunori Yorozu; Takushi Dokiya
Journal:  Jpn J Radiol       Date:  2009-12-25       Impact factor: 2.374

4.  Comparison of MRI visualization between linearly placed iron-containing and non-iron-containing fiducial markers for prostate radiotherapy.

Authors:  Osamu Tanaka; Hisao Komeda; Masayoshi Tamaki; Kensaku Seike; Shota Fujimoto; Eiichi Yama; Shigeki Hirose; Masayuki Matsuo
Journal:  Br J Radiol       Date:  2017-11-28       Impact factor: 3.039

5.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

6.  Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy.

Authors:  Jeremiah W Sanders; Rajat J Kudchadker; Chad Tang; Henry Mok; Aradhana M Venkatesan; Howard D Thames; Steven J Frank
Journal:  Radiol Artif Intell       Date:  2022-01-26

7.  Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study.

Authors:  X Allen Li; An Tai; Douglas W Arthur; Thomas A Buchholz; Shannon Macdonald; Lawrence B Marks; Jean M Moran; Lori J Pierce; Rachel Rabinovitch; Alphonse Taghian; Frank Vicini; Wendy Woodward; Julia R White
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-01       Impact factor: 7.038

8.  A Bayesian nonrigid registration method to enhance intraoperative target definition in image-guided prostate procedures through uncertainty characterization.

Authors:  Jennifer Pursley; Petter Risholm; Andriy Fedorov; Kemal Tuncali; Fiona M Fennessy; William M Wells; Clare M Tempany; Robert A Cormack
Journal:  Med Phys       Date:  2012-11       Impact factor: 4.071

9.  Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.

Authors:  Giovanni Fellin; Maria A Mirri; Luigi Santoro; Barbara A Jereczek-Fossa; Claudio Divan; Salvatore Mussari; Francesco Ziglio; Beniamino La Face; Fernando Barbera; Michela Buglione; Laura Bandera; Barbara Ghedi; Nadia G Di Muzio; Andrea Losa; Paola Mangili; Luciano Nava; Renato Chiarlone; Nunzia Ciscognetti; Emilio Gastaldi; Federica Cattani; Ruggero Spoto; Andrea Vavassori; Francesca R Giglioli; Alessia Guarneri; Valentina Cerboneschi; Marcello Mignogna; Mauro Paoluzzi; Valentina Ravaglia; Costanza Chiumento; Stefania Clemente; Vincenzo Fusco; Roberto Santini; Marco Stefanacci; Francesco P Mangiacotti; Marco Martini; Tiziana Palloni; Giuseppe Schinaia; Grazia Lazzari; Giovanni Silvano; Stefano Magrini; Umberto Ricardi; Riccardo Santoni; Roberto Orecchia
Journal:  Br J Radiol       Date:  2016-07-07       Impact factor: 3.039

10.  Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life.

Authors:  Alexander A Harris; Megan Wu; Jacqueline M Deirmenjian; Steven M Shea; Hyejoo Kang; Rakesh Patel; Derek Fielder; Michael L Mysz; Matthew M Harkenrider; Abhishek A Solanki
Journal:  Brachytherapy       Date:  2020-11-05       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.